GlassScriptPhysician profile
Jorge B Caballero
NPI 1356383384
$7,245.91
in general payments reported to CMS, 2019-2025
57 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $886 · 2021: $1,520 · 2022: $1,433 · 2023: $1,190 · 2024: $1,374 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,301.48 | 2019-2025 | Bexsero, Shingrix, Rotarix |
| Abbvie INC. | $1,110.58 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $984.50 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $400.13 | 2019-2022 | |
| Lilly USA, LLC | $362.69 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $305.12 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $248.97 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $186.34 | 2021-2024 | |
| Amgen INC. | $185.22 | 2021-2023 | Otezla, Enbrel |
| Astellas Pharma US INC | $165.63 | 2021-2024 | Veozah, Myrbetriq |
| Supernus Pharmaceuticals, INC. | $157.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $155.70 | 2021-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $151.71 | 2022-2025 | |
| Abbott Laboratories | $118.26 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.87 | 2023-2024 | Jardiance, Synjardy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Caballero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.